They improve anti-tumor T-cell immunity mainly by blocking the interaction of the coinhibitory receptor programmed cell death-1 (PD-1) with its main ligand programmed death-ligand 1 (PD-L1) (4, 5). Here, PDCD1 is linked to neoplasm.